Oxyless was founded in 2010, with the purpose of developing an innovative new bloodline for hemodialysis.
We are proud to have developed a novel bloodline that reduces blood-air contact by 99.1%. This may provide an alternative strategy in managing renal anemia.
The Oxyless team are committed to improving dialysis patients’ outcomes and reducing the costs
of dialysis treatments.
Oxyless are building close working relationships with nephrologists worldwide to highlight the strengths of the bloodline, so that more dialysis patients can experience the benefits.